je.st
news
TG Therapeutics, Inc. Announces Presentations of Its Proprietary...
2015-05-31 18:38:42| Logistics - Topix.net
TG Therapeutics, Inc. Announces Presentations of Its Proprietary Combination of TG-1101 Plus TGR-1202 as Well as TGR-1202 as a Single Agent in Ongoing Phase I/Ib Dose Escalation Clinical Studies Triple therapy cohort of the combination study to be presented separately as an oral presentation tomorrow morning, Monday, June 1st, 2015, at 51st American Society of Clinical Oncology Annual Meeting Data from both studies continues to demonstrate a favorable safety profile with a high level of activity and a significant dose-response relationship observed 85% CLL/SLL patients treated at the higher doses of 1202 as a single agent and in combination with TG-1101 achieved a nodal response, with most CLL patients achieving a Partial Response per iwCLL criteria with patients on study pending further assessment 50% Overall Response Rate in Follicular Lymphoma patients treated with the higher doses of ... (more)
Tags: presentations
announces
proprietary
therapeutics
Category:Transportation and Logistics
Latest from this category |
All news |
||||||||||||||||||
|
|||||||||||||||||||